Roger W. Sommi, PharmD, BCPP, FCCP, is affiliated with the School of Pharmacy at the University of Missouri-Kansas City. His publications on Psychiatrist.com from 2015 to 2024 focus on schizophrenia, schizoaffective and psychotic disorders, and metabolic disorders. His research includes studies on aripiprazole lauroxil regimens, metabolic parameter changes in psychiatric patients, and comparisons of long-acting injectable versus oral risperidone in schizophrenia with co-occurring alcohol use disorder.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
